Implementation, target population, compliance and barriers to risk guided therapy

Area of Science:

• Cardiology
• Public Health
• Health Policy

Background:

• Cardiovascular disease (CVD) is the leading cause of mortality globally.
• Significant disparities exist between clinical guidelines for CVD risk factor management and actual patient care.
• Preventative medication for CVD risk factors is underutilized, particularly in low-income countries.

Purpose of the Study:

• To identify barriers to the implementation of cardiovascular disease clinical guidelines.
• To explore strategies for improving adherence to CVD prevention recommendations.
• To highlight the importance of addressing implementation gaps for better patient outcomes.

Main Methods:

• Review of existing literature on cardiovascular disease guideline implementation.
• Analysis of barriers including clinical trial representativeness, medication adherence, guideline awareness, and physician-related factors.
• Identification of potential strategies for improving guideline adherence and CVD prevention.

Main Results:

• Clinical trial populations often differ from real-world patients, complicating treatment.
• Adverse effects, complex dosing, lack of awareness, perceived recommendations unrealistic, physician time constraints, and prescription costs impede guideline adherence.
• Underuse of preventative therapies contributes to continued high CVD mortality.

Conclusions:

• Overcoming barriers to guideline implementation is essential for effective cardiovascular disease prevention.
• Strategies include targeted research, increased funding, policy promotion of healthy lifestyles, physician/patient education, and systemic quality monitoring.
• Multidisciplinary teams and digital support systems show promise in improving adherence to lifestyle changes and pharmacotherapy.